Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921
12/24/2015 - 06/30/2020 (PI)GlaxoSmithKline, Inc.
Abatacept (CTLA4_Ig) For the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyaugiitis (Wegener's) (ABROGATE)
03/10/2015 - 03/09/2020 (Subcontract PI)Cleveland Clinic Foundation Bristol-Myers Squibb
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculiti
02/28/2017 - 02/27/2020 (PI)ChemoCentryx, Inc.
Vasculitis Clinical Research Consortium-ARAMIS Pilot
01/01/2017 - 08/31/2019 (Subcontract Co-PI)Trustees of the University of Pennsylvania NIH NIAMS5U54AR057319-16
Prospective, Observational Safety Study of Patients with Wegener's Granulomatosis (Granulomatosis with Polyangitis) or Microscopic Polyangitis Treated with Rituximab
03/01/2012 - 02/28/2019 (PI)Hoffmann-La Roche Inc (Foreign)
A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Stand
09/24/2014 - 12/31/2018 (PI)GlaxoSmithKline, Inc.
Vasculitis Clinical Research Foundation
09/01/2017 - 08/31/2018 (Subcontract PI)Trustees of the University of Pennsylvania NIH NIAMS5U54AR057319-15
Adaptation and Validation of PROMIS for use in Vasculitis
09/15/2012 - 08/31/2018 (Subcontract PI)Trustees of the University of Pennsylvania NIH NIAMS5R01AR064153-04
Identification of Shared Molecular Targets
07/01/2017 - 06/30/2018 (Subcontract PI)Trustees of the University of Pennsylvania NIH NCATS9U01TR001263-11
Novel Methods for the Conduct of Clinical Trials
06/01/2016 - 05/31/2018 (Subcontract PI)Trustees of the University of Pennsylvania NIH NHLBI4R01HL115041-04
Showing 10 of 24 results.
Show All Results